{
  "docId": "019de073-187a-71e9-a3c0-2f4159454068",
  "docSlug": "48ce63a07f3c546c39a71c96ea43409e",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 40 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 40,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 18,
  "notes": "Slide 18 of a presentation, likely AstraZeneca H1 2022 results.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-187a-71e9-a3c0-2f4159454068/18",
  "deckHref": "/decks/019de073-187a-71e9-a3c0-2f4159454068",
  "deckJsonHref": "/decks/019de073-187a-71e9-a3c0-2f4159454068.json",
  "deckAnchorHref": "/decks/019de073-187a-71e9-a3c0-2f4159454068#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.28,
        "x": 0.67,
        "y": 0.25
      },
      "kind": "chart",
      "text": "V&I Revenue 2021-2022",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c9fcd1c7-7630-4c54-99a2-eb778a22665c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.28,
        "x": 0.35,
        "y": 0.25
      },
      "kind": "chart",
      "text": "R&I Revenue 2021-2022",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f32bd9dc-70f7-44f0-9292-1800146db807",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.28,
        "x": 0.04,
        "y": 0.25
      },
      "kind": "chart",
      "text": "CVRM Revenue 2021-2022",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f6e5e468-2b5e-40cd-bef9-30e77e252b4e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.95,
        "x": 0.03,
        "y": 0.94
      },
      "kind": "disclaimer",
      "text": "1. IQVIA Mar – May R3M Volume Growth... 2. IQVIA Monthly SOB SUA Retail... 3. IQVIA ELAAD data 24 June 2022...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f741fcfd-993b-4567-aac6-2b4f620f5839",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.28,
        "x": 0.04,
        "y": 0.72
      },
      "kind": "list",
      "text": "Farxiga +62%, HFrEF and CKD launches continue; Fastest growing SGLT2i globally",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2aba25a4-c0c4-4422-b7c0-9f89719f0c99",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.28,
        "x": 0.67,
        "y": 0.72
      },
      "kind": "list",
      "text": "Evusheld $914m; Vaxzevria $1.6bn, vast majority of initial contracts fulfilled in H1",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b4afc2e8-1098-45a4-8f34-c5a6294c69fd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.28,
        "x": 0.35,
        "y": 0.72
      },
      "kind": "list",
      "text": "Fasenra +18%, leading IL-5 biologic; Tezspire achieved 13% NBRx share in US; Saphnelo achieved 24% NBRx share in US",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ed240d31-8a33-4838-8b1b-b826eaf551bf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.65,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "Farxiga's second blockbuster quarter with $1.1bn revenues",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5fec1c26-74ef-42f0-823a-3253d6851baa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "BioPharmaceuticals: H1 2022",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2cd3b1e5-dd19-4f7d-b358-7e62c0da9c96",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "8b877fc4-145f-4d24-8442-7d195572066c",
      "evidence": "Fasenra +18%, leading IL-5 biologic; Tezspire achieved 13% NBRx share in US; Saphnelo achieved 24% NBRx share in US",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}